BRIDGE HCVBuilding Bridges to Reach People Who Inject Drugs With the Goal to Eliminate HCV
Collier MG, et al. Am J Public Health. 2015;105(2):302–303.
Mehta SH, Thomas DL. J Hepatol. 2016;65(1):5-6.
Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation.
McLellan AT, et al. JAMA. 2000;284(13):1689-1695.
Efficacy and safety of edipasvir/sofosbuvir with and without ribavirin in patients with chronic HCV genotype 1 infection receiving opioid substitution therapy: analysis of phase 3 ION trials.
Grebely J, et al. Clin Infect Dis. 2016;63(11):1405-1411.
Efficacy and safety of sofosbuvir/velpatasvir in patients with chronic hepatitis C virus infection receiving opioid substitution therapy: analysis of phase 3 ASTRAL trials.
Grebely J, et al. Clin Infect Dis. 2016;63(11):1479-1481.
Elbasvir/grazoprevir to treat hepatitis C virus infection in persons receiving opioid agonist therapy: a randomized trial.
Dore GJ, et al. Ann Intern Med. 2016;165(9):625-634.
Wurcel AG, et al. Clin Infect Dis. 2015;61(12):1840-1849.
Facilitators of HCV treatment adherence among people who inject drugs: a systematic qualitative review and implications for scale up of direct acting antivirals.
Rich ZC, et al. BMC Public Health. 2016;16:994.
Kim AY, Page K. J Infect Dis. 2013;208(12):1929-1931.
Incidence, risk factors, and prevention of hepatitis C reinfection: a population-based cohort study.
Islam N, et al. Lancet Gastroenterol Hepatol. 2017;2(3):200-210.
Medical and behavioral approaches to engage people who inject drugs into care for hepatitis C virus infection.
Gonzalez SA, et al. Addict Disord Their Treat. 2017;16(2 suppl 1):S1-S23.
U.S. Department of Health and Human Services, 2017.
Outcomes from a large 10-year hepatitis C treatment programme in people who inject drugs: no effect of recent or former injecting drug use on treatment adherence or therapeutic response.
Elsherif O, et al. PLoS One. 2017;12(6):e0178398.
SOF/VEL/VOX for 8 or 12 weeks is well tolerated and results in high SVR12 rates in patients receiving opioid substitution therapy.
Grebely J, et al. European Association for the Study of the Liver. The International Liver Congress™ − EASL 2017. April 19-23, 2017; Amsterdam, The Netherlands.
Sustained drug use changes after hepatitis C screening and counseling among recently infected persons who inject drugs: a longitudinal study.
Bruneau J, et al. Clin Infect Dis. 2014;58(6):755-761.
Wilson DP, et al. Int J Drug Policy. 2015:26(suppl 1):S5-S11.
Falade-Nwulia O, Sulkowski M. J Hepatol. 2017;66(2): 267-269.
Younossi Z, et al. Am J Manag Care. 2017;23(2):107-112.
Grebely J, Dore GL. Clin Liver Dis. 2017;9(4):77-80.
Have You Ever Injected Drugs? What You Need to Know About Hepatitis C
Current or past injection drug use puts you at high risk for hepatitis C infection. But there is good news for those who are infected: New treatments are available that cure most people—even injection drug users. This video provides important information on your risk for Hepatitis C, getting tested, and—if you're infected—getting cured.
Building Bridges to Reach People Who Inject Drugs with the Goal to Eliminate HCV
The PCPs Role in Preventing HIV
What Do You Know About PrEP?
Optimizing Use of Clinical Evidence & Pharmacoeconomic Models in Managed Care
Advances in the Diagnosis and Treatment of Nonalcoholic Steatohepatitis
What Do You Know About PrEP?
Got it? Treat it!
The Critical Role of the Community Pharmacist
Bringing Local Communities Together to Eliminate Coinfection Through Knowledge and Partnerships.
Volume 1: Rapid ART Initiation: A New Addition to the HIV-Care Tool Box